

# Rajasthan Medical Services Corporation Limited

Gandhi Block, Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066 , 2228064 Fax No. 0141-2228065 Website: <http://rmsc.health.rajasthan.gov.in>

CIN:U24232RJ2011SGC035067

E mail : [edprocurement@gmail.com](mailto:edprocurement@gmail.com), and [rmsc@nic.in](mailto:rmsc@nic.in)

Ref. No.:- F.02(225)/RMSC/PROCUREMENT/DRUG/NIB-05/2017/ 720


Dated: 23.05.2017

## Corrigendum – 1

**Subject:-** Amendments in technical specifications, conditions etc.

Ref. -Pre bid meeting dated 09.05.2017 for the Bid reference no  
F.02(225)/RMSC/PROCUREMENT/DRUG/NIB-05/2017/650 Dated:02.05.2017  
(Technical bid opening due on dated – 06.06.2017)

S. No	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.).
1.	<p><b>Clause 2(b) ELIGIBILITY CRITERIA</b> Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years (2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16) shall not be less than Rs. 20 Crores. For MSME units of Rajasthan, the average annual turnover in the last three financial years (2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16) should not be less than Rs. 2 Crores. For drug items falling in the category of Disinfectants &amp; Antiseptics, Eye preparations and Ear drops etc (Item code – 117, 536, 687) bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Cr</p> <p><b>Clause 5(m) TECHNICAL BID and ANNEXURE-III</b> Annual turnover statement for 3 years i.e., 2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16 in the format given in Annexure-III certified by the practicing Chartered Accountant.</p> <p><b>Clause 5(n) TECHNICAL BID</b> Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16 duly certified by the practicing Chartered Accountant.</p>	<p><b>Clause 2(b) ELIGIBILITY CRITERIA</b> Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years (2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16 <u>or 2014-15, 2015-16 and 2016-17</u>) shall not be less than Rs. 20 Crores. For MSME units of Rajasthan, the average annual turnover in the last three financial years (2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16 <u>or 2014-15, 2015-16 and 2016-17</u>) should not be less than Rs. 2 Crores. For drug items falling in the category of Disinfectants &amp; Antiseptics, Eye preparations and Ear drops etc (Item code – 117, 536, 687) bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Cr. <b><u>For Item code – NE11 bidder's firms average annual turnover of last three financial years should not be less than Rs. 10 Cr.</u></b></p> <p><b>Clause 5(m) TECHNICAL BID and ANNEXURE-III</b> Annual turnover statement for 3 years i.e., 2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16 <u>or 2014-15, 2015-16 and 2016-17</u> in the format given in Annexure-III certified by the practicing Chartered Accountant.</p> <p><b>Clause 5(n) TECHNICAL BID</b> Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2012-13, 2013-14 and 2014-15 or 2013-14, 2014-15 and 2015-16 <u>or 2014-15, 2015-16 and 2016-17</u> duly certified by the practicing Chartered Accountant.</p>




2. **Clause 5(i) TECHNICAL BID**  
 WHO-GMP (WHO – Good manufacturing practices Certificate) Certificate issued by the Licensing Authority. The WHO-GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

**Clause 5(i) TECHNICAL BID**  
 In the existing condition of WHO-GMP in the clause, it is relaxed to GMP for below mentioned item codes :-

Code No.	Name of item with specification
100A	Chloroquine Phosphate Suspension IP 50 mg/5ml
393	Multivitamin Drops Each ml contains Vit-A -3000 IU, Vit-D3-300 IU, Vit-B1 -1mg, Riboflavine Phosphate Sodium -2mg, D-Panthenol -2.5mg, Niacinamide -10mg, Pyridoxine HCL-1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg
448	Iron and Folic Acid Suspension. Each 5ml contains Ferrous Fumerate equivalent to elemental iron 100mg, Folic Acid 500 mcg

GMP (Good manufacturing practices Certificate) Certificate issued by the Licensing Authority. The GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of GMP. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

3. **Clause 2© ELIGIBILITY CRITERIA**  
**Clause 5 (i) (j) TECHNICAL BID**  
 Annexure-XV Ref. Clause No. 2 (c)

Code No.	Name of item with specification
393	Multivitamin Drops Each ml contains Vit-A -3000 IU, Vit-D3-300 IU, Vit-B1 -1mg, Riboflavine Phosphate Sodium -2mg, D-Panthenol -2.5mg, Niacinamide -10mg, Pyridoxine HCL-1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg

**Clause 2© ELIGIBILITY CRITERIA**  
**Clause 5 (i) (j) TECHNICAL BID**  
 Annexure-XV Ref. Clause No. 2 (c)

Code No.	Relaxation in Condition of Product permission, Market Standing Certificate and Performance Statement
393	Market standing certificate and performance Statement of the firm's formulation with similar active ingredients will be accepted. [Product should at least have all the ingredients of RMSC formulation (quantity may differ).

\*However, for all above items, the firm has to submit with bid, the product permission (from the Licensing Authority) same as per bid specifications.

4.	<b>Annexure – VIII and BoQ</b>			<b>Annexure – VIII and BoQ</b>				
	<b>Code No.</b>	<b>Name of item with specification</b>	<b>Packing Unit</b>	<b>Code No.</b>	<b>Name of item with specification</b>	<b>Amended Packing Unit</b>		
	536	Methotrexate Tablets IP 10 mg	10x10 Tablet Strip	536	Methotrexate Tablets IP 10 mg	10x10 Tablet Strip or <b>1x4 Tablet</b> (Rate should be quoted for one Tablet only)		
	NE11	Post exposure prophylaxis drugs for HIV- Drug Combination : Tenofivir 300 mg+ Lamivudine 300 mg + Efavirenz 600 mg	Combination in a single pill and packing in blister pack of 10 tabs	NE11	Post exposure prophylaxis drugs for HIV- Drug Combination : Tenofivir 300 mg + Lamivudine 300 mg + Efavirenz 600 mg	<b>30 Tablets in a Bottle</b>		
5.	<b>Annexure-VIII and BOQ:-</b>			<b>Annexure-VIII and BOQ :- Add the following drugs in the bid</b>				
				<b>Code No.</b>	<b>Name of item with specification</b>	<b>Packing Unit</b>	<b>Minimum labelled Shelf Life (In Months)</b>	<b>Estimated Bid Qty.(No. of tabs, Caps, ampoules, bottles, injections, etc.)</b>
				651	Artemether and Leumefantr in Tablet (80 mg + 480 mg)	1 x 6 Tablet Blister	24	1296870
				686	Artemether and Leumefantr in Tablet (40 mg + 240- mg)	1 x 6 Tablet Blister	24	1020620
				<p><b>BoQ :- Two drugs have been added in the bid. The BoQ is replaced with new BoQ. Please ensure that financial bid is submitted in new BOQ only.</b></p> <p><b><u>(Total Drugs in Bid 23)</u></b></p>				

**Note:-**

- It may be noted that if any type of amendments required than further corrigendum will be published and informed.
- Rest terms and conditions will remain the same.

  
**Executive Director (Proc.)**  
**RMSC**

*(Handwritten signature)*

